Logo

Takeda’s Entyvio (vedolizumab) Receives the MHLW Approval for the Maintenance Treatment of Moderate to Severe Ulcerative Colitis

Share this

Takeda’s Entyvio (vedolizumab) Receives the MHLW Approval for the Maintenance Treatment of Moderate to Severe Ulcerative Colitis

Shots:

  • The MHLW has approved the use of Entyvio (SC) as maintenance therapy for the treatment of mod to sev. UC who has had an inadequate response to existing therapies
  • The approval was based on the P-III trials (MLN0002SC-3027 & 3030) evaluating the efficacy and safety of Entyvio SC as a maintenance therapy
  • Entyvio is a humanized mAb & was designed to specifically antagonize the α4β7 integrin, inhibiting the binding of α4β7 integrin to intestinal MAdCAM-1. The therapy was currently approved as an IV formulation for UC and the maintenance of mod. to sev. UC & CD and as SC formulation for the maintenance treatment of UC
     

    Ref: takeda | Image: takeda

Click here to­ read the full press release 

Senior Editor

Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Related News/Articles

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions